Safety of Direct-Acting Antiviral Therapy Regarding Renal Function in Post-Liver Transplant Patients Infected with Hepatitis C Virus and a 100% 12-Week Sustained Virologic Response-A Single-Center Study.

•This study shows real-life data of liver transplant recipients infected with HCV and treated with DAA.•In patients with preexisting renal impairment, therapy was safe and did not alter renal function.•Noninvasive fibrosis measurement tended to improve under DAA therapy.